Released Apr 15, 2013, after the close
10-K filed Apr 15, 2013, 105 days after period end · 0001213900-13-001814
Q4 2012 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$6.68M$6.68M derived+0.4% vs Q4 2011−32.5% vs Q3 2012
Net Income-$780.32K-$780.32K derivedN/M vs Q4 2011N/M vs Q3 2012
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$2,231,608−4.1%
Operating Incomederived$363,273−64.4%
Operating Cash Flowderived-$5,012,948N/M
Free Cash Flowderived-$5,069,387N/M
Margins · derived
Gross margin33.4%−1.6 pt vs Q4 2011
Operating margin5.4%−9.9 pt vs Q4 2011
Net margin-11.7%−41.6 pt vs Q4 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2012dderived from reported figures | Q4 2011dderived from reported figures | Q4 2010dderived from reported figures |
|---|---|---|---|
| Revenue | $6.68M | $6.65M | — |
| Net Income | -$780.32K | $1.99M | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tanke Biosciences Corp · CIK 1452011 · Engraved from SEC EDGAR